Retrieved on:
Thursday, November 14, 2019
SAN DIEGO, Nov. 14, 2019 /PRNewswire/ --Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that Barry Quart, Pharm.D., President and Chief Executive Officer of Heron Therapeutics, will present at the Jefferies London Healthcare Conference on Thursday, November 21, 2019 at 5:20 p.m. GMT (12:20 p.m. EST) at the Waldorf Hilton London hotel.
Key Points:
- SAN DIEGO, Nov. 14, 2019 /PRNewswire/ --Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that Barry Quart, Pharm.D., President and Chief Executive Officer of Heron Therapeutics, will present at the Jefferies London Healthcare Conference on Thursday, November 21, 2019 at 5:20 p.m. GMT (12:20 p.m. EST) at the Waldorf Hilton London hotel.
- A live webcast of the presentation will be available on the Company's website at www.herontx.com in the Investor Resources section.
- Heron Therapeutics, Inc.is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs.
- Heron is developing novel, patient-focused solutions that apply its innovative science and technologies to already-approved pharmacological agents for patients suffering from pain or cancer.
Retrieved on:
Wednesday, November 13, 2019
SAN DIEGO, Nov. 13, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that Barry Quart, Pharm.D., President and Chief Executive Officer of Heron Therapeutics, will present at the Stifel 2019 Healthcare Conference on Tuesday, November 19, 2019 at 8:35 a.m. EST at the Lotte New York Palace hotel.
Key Points:
- SAN DIEGO, Nov. 13, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that Barry Quart, Pharm.D., President and Chief Executive Officer of Heron Therapeutics, will present at the Stifel 2019 Healthcare Conference on Tuesday, November 19, 2019 at 8:35 a.m. EST at the Lotte New York Palace hotel.
- A live webcast of the presentation will be available on the Company's website at www.herontx.com in the Investor Resources section.
- Heron Therapeutics, Inc.is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs.
- Heron is developing novel, patient-focused solutions that apply its innovative science and technologies to already-approved pharmacological agents for patients suffering from pain or cancer.
These results provide additional evidence that even in large painful surgical procedures HTX-011 can help to reduce both pain and the amount of opioid pills going out into society."
Key Points:
- These results provide additional evidence that even in large painful surgical procedures HTX-011 can help to reduce both pain and the amount of opioid pills going out into society."
- Heron submitted a New Drug Application (NDA) to the FDA for HTX-011 in October of 2018 and received Priority Review designation in December of 2018.
- Heron resubmitted an NDA to the FDA for HTX-011 in September 2019 and the FDA set a PDUFA goal date of March 26, 2020.
- Heron is developing novel, patient-focused solutions that apply its innovative science and technologies to already-approved pharmacological agents for patients suffering from pain or cancer.
Retrieved on:
Tuesday, October 22, 2019
Medicine,
Clinical medicine,
Cancer,
Antiemetics,
Oncology,
Antineoplastic drugs,
Cancer treatments,
Lactams,
Chemotherapy-induced nausea and vomiting,
Aprepitant,
Chemotherapy,
HEC The sNDA requested FDA approval to expand the recommended dosage to include the 130 mg single-dose regimen for patients receiving MEC.
Key Points:
- The sNDA requested FDA approval to expand the recommended dosage to include the 130 mg single-dose regimen for patients receiving MEC.
- CINVANTI is indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting(CINV) following both highly emetogenic cancer chemotherapy (HEC) and MEC.
- Results from two pivotal, randomized, cross-over, bioequivalence studies of CINVANTI and EMEND IV showed subjects receiving CINVANTI reported fewer adverse events than those receiving EMEND IV, including substantially fewer infusion-site reactions.
- Use of CINVANTI with other drugs that are CYP3A4 substrates may result in increased plasma concentration of the concomitant drug.
In addition, Heron has granted the underwriters of the offering a 30-day option to purchase up to an additional 1,285,714 shares of its common stock on the same terms and conditions.
Key Points:
- In addition, Heron has granted the underwriters of the offering a 30-day option to purchase up to an additional 1,285,714 shares of its common stock on the same terms and conditions.
- The offering is expected to close on or about October 8, 2019, subject to customary closing conditions.
- The gross proceeds from the offering are expected to be approximately $150million before deducting customary underwriting discounts and offering expenses.
- Cantor is acting as lead manager for the offering, and JMP Securities, Needham & Company and Northland Capital Markets are acting as co-managers for the offering.
Retrieved on:
Thursday, October 3, 2019
Finance,
Financial markets,
Money,
Stock market,
Corporate finance,
Equity securities,
Public offering,
Stock,
Underwriting,
Security,
Offering,
Share Heron intends to grant the underwriters of the offering a 30-day option to purchase up to an additional 15% of the shares sold in the public offering.
Key Points:
- Heron intends to grant the underwriters of the offering a 30-day option to purchase up to an additional 15% of the shares sold in the public offering.
- All of the shares of common stock in the offering are to be sold by Heron.
- The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.
- Cantor is acting as lead manager for the offering, and JMP Securities, Needham & Company and Northland Capital Markets are acting as co-managers for the offering.
Retrieved on:
Wednesday, October 2, 2019
The Phase 3b study included the same multimodal, oral analgesic regimen as a prior published study with liposomal bupivacaine in TKA (Mont doi: 10.1016/j.arth.2017.07.024).
Key Points:
- The Phase 3b study included the same multimodal, oral analgesic regimen as a prior published study with liposomal bupivacaine in TKA (Mont doi: 10.1016/j.arth.2017.07.024).
- Topline results of this Phase 3b study include the following:
Mean pain scores remained in the mild range through 72 hours post-surgery.
- Median consumption of opioids was 4-to-5 pills of oxycodone (22.5 morphine milligram equivalents) through 72 hours.
- These Phase 3b study results in TKA complement the positive results of HTX-011 studies in hernia repair and bunionectomy.
SAN DIEGO, Oct. 1, 2019 /PRNewswire/ --Heron Therapeutics, Inc. (Nasdaq: HRTX),a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced the appointment of Kimberly Manhard to Heron's Board of Directors.
Key Points:
- SAN DIEGO, Oct. 1, 2019 /PRNewswire/ --Heron Therapeutics, Inc. (Nasdaq: HRTX),a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced the appointment of Kimberly Manhard to Heron's Board of Directors.
- "I am pleased to welcome Kimberly to the Heron Board," said Barry Quart, Pharm.D., President and Chief Executive Officer of Heron.
- Ms. Manhard has served as Executive Vice President, Drug Development of Heron since 2016.
- From 2014 to 2016, Ms. Manhard served as a director of Heron.
"I am pleased to welcome Steve to the Heron Board," said Barry Quart, Pharm.D., President and Chief Executive Officer of Heron.
Key Points:
- "I am pleased to welcome Steve to the Heron Board," said Barry Quart, Pharm.D., President and Chief Executive Officer of Heron.
- "Steve's executive leadership in commercial organizations and public-company board of directors experience in the biopharmaceutical industry will be invaluable to Heron.
- Since 2015, Mr. Davis has served as a director of Bellicum Pharmaceuticals, Inc. From 2012 to 2015, he served as a director of Heron, and, from 2013 to 2014, he served as Executive Vice President, Chief Operating Officer of Heron.
- Mr. Davis also served as a director of Synageva Biopharma Corp. from 2011 through its acquisition by Alexion Pharmaceuticals, Inc. in 2015.
Drugs,
Psychoactive drugs,
RTT,
Medicine,
Meloxicam,
Pain management,
Bupivacaine,
Nonsteroidal anti-inflammatory drug,
Local anesthetic,
Food and Drug Administration,
Ketamine "HTX-011 was designated by the FDA as a Breakthrough Therapy for postoperative pain management and has the potential to be an important new pain management option for patients that can significantly reduce postoperative pain, including severe pain, and help patients significantly reduce the need for opioids."
Key Points:
- "HTX-011 was designated by the FDA as a Breakthrough Therapy for postoperative pain management and has the potential to be an important new pain management option for patients that can significantly reduce postoperative pain, including severe pain, and help patients significantly reduce the need for opioids."
- HTX-011, an investigational agent, is a dual-acting, fixed-dose combination of the local anesthetic bupivacaine with a low dose of the nonsteroidal anti-inflammatory drug meloxicam.
- Heron submitted a New Drug Application (NDA) to the FDA for HTX-011 in October of 2018 and received Priority Review designation in December of 2018.
- Heron is developing novel, patient-focused solutions that apply its innovative science and technologies to already-approved pharmacological agents for patients suffering from pain or cancer.
